Recent Investment Analysts’ Ratings Updates for Intellia Therapeutics (NTLA)

Intellia Therapeutics (NASDAQ: NTLA) has recently received a number of price target changes and ratings updates:

• 11/19/2024 – Intellia Therapeutics had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $90.00 price target on the stock.
• 11/18/2024 – Intellia Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $70.00. They now have an “overweight” rating on the stock.
• 11/18/2024 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
• 11/18/2024 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at William Blair. They now have a $14.00 price target on the stock.
• 11/18/2024 – Intellia Therapeutics had its price target raised by analysts at Chardan Capital from $88.00 to $91.00. They now have a “buy” rating on the stock.
• 11/11/2024 – Intellia Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $70.00 to $60.00. They now have an “outperform” rating on the stock.
• 11/8/2024 – Intellia Therapeutics was upgraded by analysts at StockNews.com to a “sell” rating.
• 11/8/2024 – Intellia Therapeutics had its price target lowered by analysts at Barclays PLC from $76.00 to $55.00. They now have an “overweight” rating on the stock.
• 11/7/2024 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.
• 10/25/2024 – Intellia Therapeutics had its price target lowered by analysts at Citigroup Inc. from $25.00 to $19.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Intellia Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $31.00 to $20.00. They now have a “neutral” rating on the stock.
• 10/25/2024 – Intellia Therapeutics had its price target lowered by analysts at Robert W. Baird from $24.00 to $18.00. They now have a “neutral” rating on the stock.
• 10/24/2024 – Intellia Therapeutics had its price target lowered by analysts at Chardan Capital from $94.00 to $88.00. They now have a “buy” rating on the stock.

Intellia Therapeutics Trading Up 3.3 %

Shares of NASDAQ:NTLA opened at $15.21 on Thursday. The company has a market capitalization of $1.55 billion, a PE ratio of -2.80 and a beta of 1.81. Intellia Therapeutics, Inc. has a 12-month low of $12.82 and a 12-month high of $34.87. The business’s fifty day simple moving average is $17.53 and its 200-day simple moving average is $21.52.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.38) EPS. Research analysts predict that Intellia Therapeutics, Inc. will post -5.13 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after acquiring an additional 659,651 shares in the last quarter. Vanguard Group Inc. increased its stake in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares in the last quarter. State Street Corp raised its holdings in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after buying an additional 780,754 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Intellia Therapeutics by 2.2% during the third quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock worth $48,164,000 after buying an additional 49,367 shares during the period. Finally, FMR LLC grew its holdings in shares of Intellia Therapeutics by 5.0% during the third quarter. FMR LLC now owns 2,339,522 shares of the company’s stock valued at $48,077,000 after buying an additional 111,104 shares during the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.